TScan Therapeutics, Inc. (TCRX)
Healthcare
- Fundamental
- 1
- Sentiment
- 1
- Technical
- 1
Do Nothing: fundamentalScore 1 and qualitativeScore 1 are below the required floor of 3, and the name also fails liquidity ($387139.50 20-day average dollar volume; $267704.07 recent 3-session regular-session dollar volume) and overnight-gap (6.66%) gates.
Company overview
TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T cell receptor-engineered T cell (TCR-T) therapies for cancer treatment. Its lead product, TSC-101, targets acute myeloid leukemia, myelodysplastic syndrome, and acute lymphoblastic leukemia. The company also collaborates with Amgen Inc. for research on Crohn's disease antigens.
Fundamental
very weakTScan faces significant financial challenges with high cash burn and going-concern risks.
Highly speculative clinical-stage biotech with heavy cash burn and deeply negative profitability. The latest SEC 10-Q includes an explicit “substantial doubt” going-concern conclusion and management runway guidance only into mid-2027, while an 8-K disclosed termination of the Amgen collaboration. Liquidity ratios are still above 1, but financing/dilution risk dominates and traditional valuation signals are mostly non-meaningful.
Sentiment
very weakSentiment is negative due to financial concerns and the termination of the Amgen collaboration.
Last ~14d media tone turned bearish (aggregator polarity_score ≈ -0.30) as Q2 results were framed as a revenue/EPS miss and reports highlighted Amgen terminating the Crohn’s collaboration (8‑K disclosed). Baseline coverage is too sparse to compute a reliable sentiment delta, and a severe red-flag cap applied due to the Q2 10‑Q’s “substantial doubt” going‑concern disclosure.
Technical
very weakThe stock is in a strong downtrend, below key moving averages with weak momentum.
Price is below SMA20/50/200, EMA9/21, and daily VWAP, while MACD remains below zero and ADX is elevated enough to confirm the dominant trend is still down; the latest decline also came on heavier volume than the prior bounce.
You’re looking at 2026-08-20 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.